Entrada Therapeutics Inc (TRDA) — Cash Flow Reinvestment Rate

Latest as of June 2024: 0.64x

Entrada Therapeutics Inc (TRDA) has a Cash Flow Reinvestment Rate of 0.64x as of June 2024, reinvesting $25.43 Million (capex $1.05 Million plus investments $-24.38 Million) from operating cash flow of $39.83 Million. Explore Entrada Therapeutics Inc capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.64x
(Capex + Investments) / Operating CF

Total Reinvested

$25.43 Million
Capex + Investments

Operating Cash Flow

$39.83 Million
USD

Capital Expenditures

$1.05 Million
USD

Entrada Therapeutics Inc Cash Flow Reinvestment Rate (2023–2023)

Historical reinvestment intensity for Entrada Therapeutics Inc across 1 annual periods. Also explore TRDA total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Entrada Therapeutics Inc (2023–2023)

Year-by-year capital reinvestment analysis for Entrada Therapeutics Inc. For live market cap and broader valuation context, see market value of Entrada Therapeutics Inc.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2023 1.03x $144.26 Million $139.80 Million $5.61 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow